Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-LN extension
2024-515280-60-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, open-label trial of ianalumab in lupus nephritis (LN) (2 arms), sponsored by Novartis. Primary endpoints: Time to renal flare, increase in immunosuppressive medication, or death and Long-term safety. Planned start May 2025; status: authorised.
02
Drugs
ianalumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2024-515280-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515280-60-00.